Romiplostim for Chemotherapy-Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors

Abstract

Romiplostim for chemotherapy-induced thrombocytopenia (CIT) is not well-studied in children. This single-center retrospective cohort study describes 24 pediatric patients with solid tumors who initiated romiplostim a median of 5 months into chemotherapy (range: 0–14 months) at a median maximum dose of 6.5 µg/kg (range: 1–10). A minority of patients achieved a decrease in cycle delays (30%) or dose reductions (13%). A comparative cohort, which did not receive romiplostim, had no difference in cycle delays (p = 0.42) or dose reductions (p > 0.99). There were no adverse events. Romiplostim was safe in children with solid tumors, but requires further prospective study of efficacy.